Home LiteratureArticle Details
PMID: 8602179 Published · ppublish English Clinical Trial Journal Article Randomized Controlled Trial Research Support, U.S. Gov't, P.H.S.

Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease.

The New England journal of medicine ·Vol. 334 ·No. 18 ·1996-05-02 ·Pages 1145-9

Hennekens CH, Buring JE, Manson JE, Stampfer M, Rosner B, Cook NR, Belanger C, LaMotte F, Gaziano JM, Ridker PM, Willett W, Peto R

Abstract

Observational studies suggest that people who consume more fruits and vegetables containing beta carotene have somewhat lower risks of cancer and cardiovascular disease, and earlier basic research suggested plausible mechanisms. Because large randomized trials of long duration were necessary to test this hypothesis directly, we conducted a trial of beta carotene supplementation. In a randomized, double-blind, placebo-controlled trial of beta carotene (50 mg on alternate days), we enrolled 22,071 male physicians, 40 to 84 years of age, in the United States; 11 percent were current smokers and 39 percent were former smokers at the beginning of the study in 1982. By December 31, 1995, the scheduled end of the study, fewer than 1 percent had been lost to follow-up, and compliance was 78 percent in the group that received beta carotene. Among 11,036 physicians randomly assigned to receive beta carotene and 11,035 assigned to receive placebo, there were virtually no early or late differences in the overall incidence of malignant neoplasms or cardiovascular disease, or in overall mortality. In the beta carotene group, 1273 men had any malignant neoplasm (except nonmelanoma skin cancer), as compared with 1293 in the placebo group (relative risk, 0.98; 95 percent confidence interval, 0.91 to 1.06). There were also no significant differences in the number of cases of lung cancer (82 in the beta carotene group vs. 88 in the placebo group); the number of deaths from cancer (386 vs. 380), deaths from any cause (979 vs. 968), or deaths from cardiovascular disease (338 vs. 313); the number of men with myocardial infarction (468 vs. 489); the number with stroke (367 vs. 382); or the number with any one of the previous three end points (967 vs. 972). Among current and former smokers, there were also no significant early or late differences in any of these end points. In this trial among healthy men, 12 years of supplementation with beta carotene produced neither benefit nor harm in terms of the incidence of malignant neoplasms, cardiovascular disease, or death from all causes.

MeSH Terms
Adult Aged Aged, 80 and over Antioxidants/therapeutic use Cardiovascular Diseases/epidemiology,mortality,prevention & control Carotenoids/therapeutic use Double-Blind Method Humans Incidence Male Middle Aged Mortality Neoplasms/epidemiology,mortality,prevention & control Proportional Hazards Models Risk beta Carotene
Chemicals
Antioxidants beta Carotene Carotenoids
Authors & Affiliations
12 authors, click to expand affiliations / ORCID
Hennekens C H
Department of Medicine, Brigham and Women's Hospital, Boston, MA 02215, USA.
Buring J E
Manson J E
Stampfer M
Rosner B
Cook N R
Belanger C
LaMotte F
Gaziano J M
Ridker P M
Willett W
Peto R
Article Info
Journal
The New England journal of medicine
Abbr.
N Engl J Med
ISSN
0028-4793
Published
1996-05-02
Pages
1145-9
Language
English
Region
United States
NLM ID
0255562
Subset
IM
Grants
NCI NIH HHS · CA-34944 · United States
NCI NIH HHS · CA-40360 · United States
NHLBI NIH HHS · HL-26490 · United States
Corrections
CommentIn
-
CommentIn
CommentIn
CommentIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]